DLB
Alternative Names: DLB - DualogicsLatest Information Update: 06 Jan 2022
At a glance
- Originator Dualogics
- Developer Dualogics; Unknown
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Triple negative breast cancer